Clinical Trials Browser

Has results × Prostatic Neoplasms × Naltrexone × Clear all

NCT01650350 2022-03-04

Low Dose Naltrexone for Metastatic Melanoma, Castrate Resistant Prostate Cancer and Renal Cancer

Phase 2 Terminated

7 enrolled 5 charts

DermatologicGenitourinary

Kidney Neoplasms, Melanoma, Prostatic Neoplasms